Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Open accessThe DOI matches its Crossref record; 170 of the 172 references it cites were found in a registry or an index.
Abstract
Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer’s disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder. However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Aβ therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD. Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions, and therefore, if we keep chasing only Aβ, it means that we cannot see the forest for the trees.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings suggest that Aβ deposition or plaque formation might not be the actual cause of the disease, but rather a result or secondary factor of the pathological process.77,148”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [77]
Experimental — accuracy not yet measuredIn the citing paper
“According to the amyloid cascade hypothesis, tau protein tangles and neuroinflammation are brought on by Aβ aggregation, which in turn leads to neuronal death and cognitive decline [90,91,92].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In 1992, this view culminated in the formulation of the original version of the amyloid cascade hypothesis (ACH) by Hardy and Higgins [12].”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 2×
“However, Aβ accumulation seems to occur through different mechanisms, being mainly due to increased production or decreased clearance in the familial and sporadic forms, respectively [27].”
BackgroundLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · cited 1×
“A total of 799 patients met the eligibility criteria for prodromal AD according to the International Working Group criteria [63], showing biomarker evidence of amyloid pathology (CSF Aβ42 levels ≤ 600 ng/L) and absence of dementia diagnosis assessed with MMSE, CDR, CDR-SB, and FCSRT (Free and Cued Selective Reminding…”
MethodTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 8×
“On the contrary, what is not controversial is the observation that there is no widespread frank neuronal death, and no neurofibrillary tangles (NTFs) are present in the vast majority of transgenic murine models of FAD.”
BackgroundInfluentialVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab is a human monoclonal antibody selectively targeting different forms of aggregated Aβ, which, like gantenerumab, shows preferred binding to fibrils over protofibrils and has low affinity for Aβ monomers [61,82].”
Background
Research works printed but not linked: 7
- Gantenerumab Mystery: How Did It Lose Potency in Phase 3? Available online: https://www.alzforum.org/news/conference- coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3 (accessed on 25 August 2023).
- Alzforum.Org API ADAD Columbia Trial Reported Results. Available online: https://www.alzforum.org/news/conference- coverage/crenezumab-secondaries-negative-gantenerumab-ole-hints-efficacy (accessed on 29 August 2023).
- Brenman, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Valenzuela, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
- Sabbagh, 2023, Response: Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1631
- Zeng, 2023, Lecanemab in Early Alzheimer’s Disease, N. Engl. J. Med., 388, 1630, 10.1056/NEJMc2301380 · DOI · Paper page
- CrossRef] [PubMed] 122.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“The toxicity mechanism of A β aggregates remains uncertain, but different perspectives exist: 77,128 A β might cause AD pathology through the loss of physiological functions during the aggregation process.”
BackgroundRecent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
Li, X., Wu, Z., Si, X., Li, J., Wu, G., & Wang, M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02699-w · Cited by 54
“Although the amyloid hypothesis remains widely accepted [9], clinical trials targeting Aβ therapies,, carried out worldwide in the last 30 years, have not yielded convincing results, suggesting that Aβ may only be a minor process in the pathogenesis of AD [10, 11].”
Systemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 54
“However, the amyloid cascade hypothesis has been challenged due to the lack of correlation between amyloid deposition and severity of cognitive deficits, as well as the relative inefficacy of the newly developed monoclonal antibodies that target Aβ [10, 11].”
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“…such as Aducanumab and Lecanemab show limited e ff ectiveness in reducing A β load without translating into signi fi cant cognitive improvements [43]. does not always This failure has led to growing skepticism about the hypothesis, prompting the exploration of alternative models and approaches…”
BackgroundAdvancements in neurodegenerative diseases: Pathogenesis and novel neurorestorative interventions
Gao, W., Jing, S., He, C., Saberi, H., Sharma, H. S., Han, F., & Chen, L. (2024) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2024.100176 · Cited by 48
Li, L., Xiong, Y., Zhang, Y., Yan, Y., Zhao, R., Yang, F., & Xie, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.009 · Cited by 35
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116684 · Cited by 27
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
Martins, A. C., Oshiro, M. Y., Alberício, F., & de la Torre, B. G. (2024) · Biomedicines · doi:10.3390/biomedicines12091992 · Cited by 26
“Lecanemab and aducanumab reinforce not only the amyloid hypothesis in AD [56,57] but also provide hope for AD patients after decades devoid of breakthroughs in the field [2,58].”
BackgroundAdvancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 46
“In a head-to-head comparison study with aducanumab, donanemab outperformed aducanumab in terms of amyloid 2 International Journal of Alzheimer ’ s Disease clearance [33].”
BackgroundBrain age as a biomarker for pathological versus healthy ageing – a REMEMBER study
Wittens, M. M. J., Denissen, S., Sima, D. M., Fransén, E., Niemantsverdriet, E., Bastin, C., Benoit, F., Bergmans, B. A., Bier, J., Deyn, P. P. D., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01491-y · Cited by 26
“…toward anti-amyloid (Aβ) therapies, which have shown potential in reducing Aβ brain accumulation, their effectiveness in improving cognition in late-stage clinical trials has been minimal, prompting reconsideration of the magnitude of the role of Aβ in Alzheimer’s disease (AD) pathogenesis [1].”
BackgroundZhang, Y. C., Li, Z., Guan, H., Qiu, Z., & Zou, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70548 · Cited by 21
“63 These outcomes underscore the difficulty in achieving meaningful clinical improvement by targeting A β after extensive downstream pathology—such as tau tangles and neurodegeneration—has already developed.”
Lin, Z., & Sun, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107790 · Cited by 16
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 17
“299-301 A signi fi cant side effect is ARIA, presenting as brain swelling (ARIA-E) or micro-hemorrhages (ARIA-H), which require careful monitoring.”
From hormones to neurodegeneration: how FSH drives Alzheimer’s disease
Xue, Y., Zuo, S., Wang, F., & Qi, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1578439 · Cited by 14
Schreiner, T. G., Croitoru, C. G., Hodorog, D. N., & Cuciureanu, D. I. (2024) · Biomedicines · doi:10.3390/biomedicines12051096 · Cited by 15
“The amyloid cascade has been reviewed extensively in several studies [25,26], including the authors’ previous works [17,27].”
Kopeć, K., Koziorowski, D., & Szlufik, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157552 · Cited by 16
“EMERGE observed a reduction in A β load and a relative 22% reduction in cognitive decline [29].”
A philosophy of science approach to the amyloid hypothesis of Alzheimer's disease
Daly, T. P. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16500 · Cited by 15
“Different reactions to clinical trial failures and those lauded as successes suggest that these debates have not been resolved (Fedele, 2023).”
Ortiz-Islas, E., Montes, P., Rodríguez-Pérez, C. E., Ruiz-Sánchez, E., Sánchez-Barbosa, T., Pichardo-Rojas, D., Zavala‐Tecuapetla, C., Carvajal, K., & Campos‐Peña, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010128 · Cited by 16
“It is administered by intravenous infusion every two weeks at a dose of 10 mg/kg [98,212].”
InfluentialCuproptosis: mechanisms and links with Alzheimer’s disease
Zheng, N., Zhou, Q., Chen, Z., Xie, L., Yang, X., Chen, Z., Wang, F., Sun, Q., Du, J., Lin, J., et al. (2025) · Journal of Neurophysiology · doi:10.1152/jn.00370.2025 · Cited by 11
Rech, M. A., Carpenter, C. R., Aggarwal, N. T., & Hwang, U. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.12.002 · Cited by 9
Chen, L., Xia, Y., Li, B., Jh, G., Zhou, X., Li, X., Chen, Z., Liu, Y., Mao, W., Zhang, J., et al. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.139065 · Cited by 10
Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases
Rahman, M. S., Islam, R., & Bhuiyan, M. I. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374408 · Cited by 10
“Recently, FDA approved two anti-amyloid anti-bodies; Aducanumab (human monoclonal antibody) and Lecanemab (humanized IgG1 antibody), which markedly reduce A β deposition in brain (Fedele, 2023).”
BackgroundCoffee and Alzheimer's disease
Mirzaei, F., Agbaria, L., Bhatnagar, K., Sirimanne, N., A'amar, N. O., Jindal, V., Thilagendra, A. G., & Raba, F. T. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.06.002 · Cited by 10
Bian, Z.-Y., Li, P., Feng, X.-Y., Zhou, Y., Cheng, F.-Y., Dong, W.-X., Xiang, P., & Tang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116794 · Cited by 8
Chen, J., Yang, W., Chen, H., Ding, X.-X., Chen, H., Zhan, C., & Jin, Z. (2024) · Inorganic Chemistry Frontiers · doi:10.1039/d4qi01945h · Cited by 8
Jayaprakash, N., & Elumalai, K. (2024) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.155 · Cited by 19
The Impact of the Exposome on Alzheimer’s Disease: The Influence of Nutrition
Monaco, M., Torazza, C., Fedele, E., & Grilli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073015 · Cited by 8
“…of these antibodies is accompanied with important side effects (up to 40% incidence) called amyloid-related imaging abnormalities (ARIA), which include brain tissue oedema (ARIA-E) and microbleeds/microhaemorrhage (ARIA-H), representing the major cause of therapy discontinuation [18].”
InfluentialSelf-citationZhang, Q., Yu, L.-K., Zhang, X.-Y., Wu, Y., Zhang, H., Wu, J.-L., Yao, Z., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352411 · Cited by 7
“45,46 49 As AD progresses, the levels of A β oligomers increase, and the number of activated astrocytes gradually rises, so the progression of AD-related neuroin fl ammation can be re fl ected by glial fi brillary acidic protein (GFAP) levels.”
Advancements in the investigation of the mechanisms underlying cognitive aging
Zou, H., Zhang, S., Cui, X., Xu, H., Zhou, Z., Cheng, D., Han, Y., Tang, Y., Dong, A., & Dong, X. (2025) · Biogerontology · doi:10.1007/s10522-025-10300-4 · Cited by 10
“These observations are consistent with the clinical symptoms exhibited by individuals diagnosed with AD (Fedele 2023).”
Identification of Molecular Correlations of GSDMD with Pyroptosis in Alzheimer's Disease
Song, T., Chen, Y., Li, C., Yao, Y., Ma, S., Yazhen, S., & Cheng, J. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073285497240226061936 · Cited by 9
Tong, P., Li, X., Li, S., Li, S., Chen, B., Chen, D., & Xia, C. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157591 · Cited by 6
Cai, X., Huang, Y., Wang, T. X., Gao, J., Tang, Y., Zhu, C., & Rong, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c17413 · Cited by 7
Cruz, P., Lam, J. M., Abdalla, J., Bell, S., Bytyci, J., Brosh‐Nissimov, T., Gill, J. S., Haidar, G., Hoerger, M. P., Maor, ., et al. (2024) · Vaccines · doi:10.3390/vaccines13010019 · Cited by 8
Artime-Naveda, F., Hevia, D., Alonso‐Arias, R., Martínez, C., Quirós-González, I., Cernuda‐Cernuda, R., Alvarez-Artime, A., Menéndez‐Valle, I., Sainz, R. M., & Mayo, J. C. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41841 · Cited by 6
“According to the A β hypothesis, the deposition of insoluble A β proteins and the formation of senile plaques lead to pathogenic processes in Alzheimer ’ s disease, which in turn produce a decrease in the concentration of A β in CSF [50], reviewed by Ref.”
Fully biodegradable dendrimers as novel nanodrugs for Amyloid-β-induced neurotoxicity
Moreira, D. A., Carvalho, E. D., Ferreira‐da‐Silva, F., Santos, S. D., Leiro, V., & Pêgo, A. P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113870 · Cited by 6
Huang, S., Lin, K., Lyu, Z.-J., & Hsiao, I. (2025) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-025-00972-1 · Cited by 6
“This upstream process triggers tau abnormalities, ultimately leading to neuronal degeneration and cognitive decline [2, 3].”
Design and application of a Tau seed amplification assay for screening inhibitors of Tau seeding
Gorski, D., Evans, H., Allison, T., Barria, C., Harrison, D., Banerjee, V., Méndez, N., Shahnawaz, M., Kaalund, S. S., Folke, J., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01855-y · Cited by 6
“Most recently, a third candidate, donanemab, also received full FDA approval, further fueling the debate over the clinical value and risk associated with these anti-Aβ drugs [5, 10, 11, 12, 13].”
Bridging the gap in the management of Alzheimer's disease using fecal microbiota transplantation
Bashir, B., Gulati, M., Vishwas, S., Hussain, M. S., Gupta, G., Kumar, P., Negi, P., Mittal, N., Dua, K., & Singh, S. K. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104052 · Cited by 6
Marine Bioactive Components and Chronic Neuroinflammation: Focus on Neurodegenerative Disease
Favari, E., & Parolini, C. (2025) · Marine Drugs · doi:10.3390/md23110446 · Cited by 4
“…of correlation between amyloid deposition and the severity of cognitive deficits, and the failure of the newly developed monoclonal antibodies directed against Abeta [43,44] prompt additional mechanisms contribute to disease pathogenesis, such as NFTs, synaptic loss, and microglial activation [45].”
Chun, H.-L., Lee, H. W., Hong, S. B., Ha, S.-S., & Yoon, K. J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261443973 · Cited by 4
“3 An alternative and increasingly supported framework is the mitochondrial dysfunction hypothesis, which emphasizes the impairments in neuronal energy metabolism and oxidative homeostasis.”
Roamcharern, N., & Yubolphan, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1810486 · Cited by 5
“…β oligomers, rather than insoluble plaques, are major contributors to synaptic dysfunction and cognitive decline in AD, although their precise pathogenic role remains under active investigation and debate (Cleary et al., 2005; Selkoe, 2008; Yang et al., 2017; Walsh and Selkoe, 2020; Fedele, 2023).”
Cardoso, F., & Schmidt, P. N. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241308482 · Cited by 4
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, J., Rodríguez, D., & Naidoo, V. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2433626 · Cited by 5
Lee, R., Kim, G., Black, E. R., & Kim, S. (2026) · Advanced Science · doi:10.1002/advs.77858 · Cited by 5
Li, X., Li, Y., Liu, Z., Zhang, Q., Zhou, Y. M., Yu, L., Liu, W., & Sang, Z. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03196-1 · Cited by 5
Soares, P., Rahaman, M., Maher, P. A., & Silverman, R. B. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00530 · Cited by 3
Latina, V., Introna, M. D., Malerba, F., Florio, R., Balzamino, B. O., Natale, G. D., Sciacca, M. F. M., Pappalardo, G., Micera, A., Pignataro, A., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02022-y · Cited by 4
Yu, L., Wang, X., Doan, T. H., Fan, Y., Bussière, T., Bacskai, B. J., & Kastanenka, K. V. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01812-9 · Cited by 5
The role of neutrophils, red blood cells, and platelets in the pathology of Alzheimer’s disease
Xu, Y., Li, X., Zhao, Q., & Xu, X. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2575110 · Cited by 3
“Despite their foundational contributions, drugs (such as Aβ-directed monoclonal antibodies [6] and tau aggregation inhibitors [7] targeting these pathways have yielded limited therapeutic efficacy.”
Xu, Z., Xu, W., He, J., Qian, J., Wang, H., Li, C., & Zhou, X. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70771 · Cited by 4
“The cleaved Aβ mostly contains 27–43 amino acids and is deposited by cytoendocrine to intercellular polymerization [34].”
The mechanisms and strategies for Alzheimer’s disease prevention: An update
Han, M., Wang, N., Song, M., Liu, C., Wu, Y., Yin, J., Jin, L., Jin, W., & Gao, Z. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.007 · Cited by 3
“Under physiological conditions, the production and clearance of Abeta are in equilibrium 14 .”
Hafez, M. M., Abbas, H. A., Shoman, N. A., Soubh, A. A., Aly, O., Sallam, M. F., Seliem, M. A., & Malaak, F. A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13829-7 · Cited by 3
“Individuals with high reserves can function normally despite the pathology, whereas individuals with poor reserves will deteriorate irrespective of the treatment, thereby diluting the observed effects in mixed populations entering trials [45, 136].”
Gaur, A., Singh, Y. P., Sharma, R. K., & Bainsal, N. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400742 · Cited by 4
Czarnota-Łydka, K., Kucwaj‐Brysz, K., Mordyl, B., Głuch‐Lutwin, M., Karcz, T. P., Jastrzębska‐Więsek, M., Partyka, A., Dąbrowska, M., Satała, G., Sudoł-Tałaj, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118026 · Cited by 3
Anti-amyloid-beta treatments in Alzheimer’s disease: When neurologists turn into cheerleaders
Olluri, A. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108237 · Cited by 3
Wang, N., Li, X., Jiang, X., Ning, X., Zhou, L., Liu, W., Wu, Q., Wang, X., Xing, Y., Qi, Z., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04982-7 · Cited by 2
“It is mainly manifested as cognitive dysfunction, including learning, memory, language barriers, executive function and perceptual motor skills [1].”
Development of novel caffeic acid derivatives as multifunctional agents for the treatment of AD
Hu, K., Yang, J., Zhang, Q., Wang, X., Xu, Y.-J., Zhang, Y., Tan, Z., Liu, W., Chen, R., & Sang, Z. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03416-2 · Cited by 2
Stefano, G. B., Büttiker, P., Weissenberger, S., Raboch, J., & Anders, M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101217 · Cited by 4
Therapeutic Potential of Ishige okamurae Yendo as a Multi-Target Inhibitor Against Dementia Symptoms
Kwon, O. Y., & Lee, S. H. (2025) · Life · doi:10.3390/life15111699 · Cited by 2
“Sub-stantial efforts are underway to develop anti-dementia therapies, and several candidates are in preclinical stages, providing hope to affected individuals [11,12].”
Alzheimer Syndrome or Age-Related Dementia—History, Therapy and Prevention
Bermejo‐Pareja, F., & del Ser, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217752 · Cited by 3
“We can summarize Herrup’s concise critique of the ACH [24,104]: (a) excess β A alone does not cause AD in humans or mice; (b) its elimination does not cure human AD; (c) the pharmacological suppression of β A production via APP manipulation does not cure AD and weakens both mice and humans…”
Katsogiannou, A., Karta, D., Stefano, A. D., Öner, S., Arslan, M. E., Mardinoğlu, A., Türkez, H., Vassiliou, S., & Cacciatore, I. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100235 · Cited by 2
Mucke, H. A. (2025) · Drug repurposing · doi:10.58647/drugrepo.25.1.0003 · Cited by 1
Sun, T., Li, Z., Xiao, B., Yang, J., Han, M., Zhang, J., Liu, S. B., Ma, H., Song, J., Su, Y., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120735 · Cited by 1
Analysis of the dual role of amyloid-beta in Alzheimer’s disease through multi-omics integration
Guo, J., Lu, X., Qiu, L., Xue, W., Fu, H., Wang, K., & Wang, Y. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00872 · Cited by 2
Han, Z., Fu, W., Dai, M., Lu, R., Yu, J., Dong, W., & Sang, Z.-P. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01026h · Cited by 1
DOSE: a lifestyle philosophy for dementia prevention informed by drug development and epidemiology
Daly, T. P. (2024) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2023-0112 · Cited by 2
Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy
Høilund‐Carlsen, P. F., Alavi, A., Costa, T., Neve, R. L., Revheim, M.-E. R., & Barrio, J. R. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261417548 · Cited by 1
Song, T., Yao, Y., & Yazhen, S. (2024) · Pharmacology & Pharmacy · doi:10.4236/pp.2024.151001 · Cited by 1
Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa
Fonseca, B. S., Cordeiro, M. H. D. L., Abreu, P. H., & Takahashi, Y. (2025) · Revista Sociedade Científica · doi:10.61411/rsc202593118
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.009 · Cited by 2
A Mechanical Theory Explaining Neural Function, Alzheimer's Disease, and EpilepsyPreprint
Moneymaker, V. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5237631
Sandberg, A. A., Puttagunta, S., Duval, N., Fleming, H., Koza, L. A., Hieber, K., Holsopple, J., Reyna, M., Paredes, D., & Linseman, D. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251338323 · Cited by 1
Shang, Z.-T., Huang, X.-Y., Xiong, L., Xu, Z., Liu, H.-X., & Yu, C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352545
“23 Recent studies have found that AD may be an autoimmune disease, and that A β acts as a host defense peptide with multiple cytokine activities such as antimicrobial and immuno-modulatory.”
Thottempudi, N., Franke, O., Samara, V. C., Musali, S. R., & Tabaac, B. J. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001978
ANTICORPOS ANTI-AMILOIDE NO TRATAMENTO DA DOENÇA DE ALZHEIMER: EFICÁCIA, MECANISMOS E AVANÇOS
Duarte, A. C. G., KLANK, A., FONSECA, B. S., Lima, E. G., Santos, E., Cardoso, L. P. V., Cordeiro, M. H. D. L., ABREU, P. H., Freire, V. N. D. F., & Takahashi, Y. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-257-4.7
The Role of T Cells in Alzheimer's Disease
Lin, Y., Zhao, H., Meng, D., & Wang, M. (2025) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2025061107
Ivanova, A., Chmelyuk, N. S., Kuzmichev, I., Shilyaeva, M., & Abakumov, M. A. (2025) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2025.061
Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease
Adeniji, A. O., Johnson, C., & Mody, V. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00020-x
Wittens, M. M. J., Denissen, S., Sima, D. M., Fransén, E., Niemantsverdriet, E., Bastin, C., Benoit, F., Bergmans, B. A., Bier, J.-C., de Deyn, P. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26043755
Wittens, M. M. J., Denissen, S., Sima, D. M., Fransén, E., Niemantsverdriet, E., Bastin, C., Benoit, F., Bergmans, B. A., Bier, J.-C., de Deyn, P. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26043836
Identification of potential BACE-1 selective inhibitors against Alzheimer’s disease
Barros, A. C., do Bomfim, M. R., Taranto, A. G., & Leite, F. H. A. (2026) · Chemical Papers · doi:10.1007/s11696-026-04694-9 · Cited by 1
Wen, H., Dong, Y., & Wang, R. (2026) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273400444251015050402
Peng, W., Chung, K. B., Al-Qazzaz, A., Straut, A., O’Banion, M. K., Lawrence, B. P., Dirksen, R. T., & Onukwufor, J. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.25.714217
Muhammad, Y. A. (2026) · Preprints.org · doi:10.20944/preprints202604.0104.v1
In vitro and in vivo assessment on memory improvement of Lac Tien Thang
Oanh, H. H., & Thanh, C. L. (2026) · Plant Science Today · doi:10.14719/pst.11613
Luo, R., Zhang, Y., Tan, X., & 邵龙泉 (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.05.021
Kariminejad-Farsangi, H., Kariminejad-Farsangi, H., Mir, Y., Sheibani, V., & Joushi, S. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05576-0
“Recently approved anti-amyloid therapies, including lecanemab and donanemab, represent the first disease-modifying approaches targeting amyloid pathology, although their clinical benefits and long-term efficacy remain to be fully established [6 ].”
Sharma, D. K., & Prasad, C. S. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2683967
Carrasco, M., Guzman, L., Barroso, E., Olloquequi, J., Cano, A., Ureña, J., Verdaguer, E., Prohens, R., Fortuna, A., Auladell, C., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02321-9
Schmidt, P., & Preskorn, S. H. (2026) · medRxiv · doi:10.64898/2026.06.05.26353604
Huang, Q., Zuo, Y., Xie, Y., Liu, Z., Wang, L., Xu, H., Yu, M., & Liu, C. (2026) · Biomaterials Science · doi:10.1039/d6bm00624h
New Insights into Drug Development and Immunotherapy for Alzheimer’s Disease
Gayen, S., Roy, S., Uddin, M. A., & Sukul, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010014
Han, J., Wu, S., Cui, X., Zhou, X., Yu, Q., Cheng, Q., Lu, Z., & Zong, S. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.07.021
Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease
Li, S., Gu, J., Xu, Z., He, C., & Yu, C. (2026) · BMC Medicine · doi:10.1186/s12916-026-05088-0
“…deposition of Aβ are recognized as the pivotal initiating event, which triggers a cascade of downstream pathological processes, including hyperphosphorylation of tau protein, neuroinflammatory responses, and synaptic loss, ultimately leading to neuronal dysfunction and cognitive impairment [5, 6].”
Yang, G., Xu, X., & Xu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1893545 · Cited by 1
“For decades, the amyloid cascade hypothesis has provided a conceptual framework in which A b accumulation is considered the initiating event that ultimately leads to tau pathology, synaptic failure, and cognitive decline (4 – 6).”
ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ПЕПТИДНЫХ ПРЕПАРАТОВ В ТЕРАПИИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
Климов, Н. А., Орлов, Д. С., Гришина, Т. В., Леонова, Л. Е., & Валерьевна, Ш. О. (2026) · Успехи геронтологии · doi:10.34922/ae.2026.39.4.002
Hassan, M., Bhatti, S. G., Yasir, M., Chun, W., & Kloczkowski, A. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c02284
Metadata
- Authors
- Fedele, E.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Corresponding author
- Fedele, Ernesto
- ORCID
- Fedele, Ernesto
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-24
- Volume
- 24
- Issue
- 19
- Pages
- 14499
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10578107
- OpenAlex
- W4386996842
- Cited by
- 102
- References
- 172
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 26 · 2023: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Funders
- The University of Genoa
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid therapy, amyloid hypothesis, amyloid-beta, aducanumab, lecanemab, donanemab, memory formation, amyloid pathogenesis, clinical trial efficacy
- MeSH terms
- Alzheimer Disease, Amyloid, Brain, Humans, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.